Nuveen
KRYS icon

Nuveen’s Krystal Biotech KRYS Stock Holding History

Nuveen’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$54.5M Buy
146,520
+3,152
+2% +$942K 0.01% 656
2026
Q1 		$37M Sell
143,368
-45,726
-24% -$12.2M 0.01% 788
2025
Q4 		$46.6M Sell
189,094
-8,284
-4% -$1.74M 0.01% 685
2025
Q3 		$34.8M Buy
197,378
+9,359
+5% +$1.4M 0.01% 800
2025
Q2 		$25.8M Sell
188,019
-46,161
-20% -$6.78M 0.01% 940
2025
Q1 		$42.2M Sell
234,180
-69,935
-23% -$11.8M 0.01% 695
2024
Q4 		$47.6M Sell
304,115
-7,740
-2% -$1.37M 0.01% 671
2024
Q3 		$56.8M Sell
311,855
-24,315
-7% -$4.69M 0.02% 598
2024
Q2 		$61.7M Buy
336,170
+5,728
+2% +$962K 0.02% 542
2024
Q1 		$58.8M Buy
330,442
+14,977
+5% +$2.08M 0.02% 576
2023
Q4 		$39.1M Buy
315,465
+53,231
+20% +$5.9M 0.01% 729
2023
Q3 		$30.4M Buy
262,234
+111,395
+74% +$13.6M 0.01% 793
2023
Q2 		$17.7M Buy
150,839
+97,908
+185% +$10M 0.01% 1153
2023
Q1 		$4.24M Sell
52,931
-4,481
-8% -$352K ﹤0.01% 1984
2022
Q4 		$4.55M Sell
57,412
-27,913
-33% -$2.07M ﹤0.01% 1967
2022
Q3 		$5.95M Sell
85,325
-31
-0% -$2.24K ﹤0.01% 1800
2022
Q2 		$5.6M Buy
85,356
+1,097
+1% +$68.2K ﹤0.01% 1874
2022
Q1 		$5.64M Buy
84,259
+6,081
+8% +$380K ﹤0.01% 1991
2021
Q4 		$5.47M Sell
78,178
-4,122
-5% -$240K ﹤0.01% 2066
2021
Q3 		$4.3M Buy
82,300
+14,090
+21% +$834K ﹤0.01% 2298
2021
Q2 		$4.64M Buy
68,210
+15,914
+30% +$1.11M ﹤0.01% 2294
2021
Q1 		$4.03M Buy
52,296
+4,105
+9% +$298K ﹤0.01% 2269
2020
Q4 		$2.89M Buy
48,191
+1,217
+3% +$60.8K ﹤0.01% 2324
2020
Q3 		$2.02M Buy
46,974
+2,774
+6% +$120K ﹤0.01% 2383
2020
Q2 		$1.83M Buy
44,200
+2,524
+6% +$121K ﹤0.01% 2373
2020
Q1 		$1.8M Buy
41,676
+2,189
+6% +$114K ﹤0.01% 2242
2019
Q4 		$2.19M Sell
39,487
-1,145
-3% -$56.2K ﹤0.01% 2387
2019
Q3 		$1.41M Buy
40,632
+5,450
+15% +$244K ﹤0.01% 2548
2019
Q2 		$1.42M Buy
+35,182
New +$1.15M ﹤0.01% 2592

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Nuveen's KRYS Position: Q2 2026 in Review

Nuveen increased its Krystal Biotech (KRYS) stake by 2.2% in Q2 2026, buying an estimated $942K and bringing the position to 146,520 shares worth $54.5M. The position accounts for 0.01% of the portfolio, ranked #656.

Nuveen first reported a position in KRYS in Q2 2019 and has held it in 29 quarters since. The position peaked at $61.7M in Q2 2024. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Nuveen held 146,520 shares of Krystal Biotech worth $54.5M as of Q2 2026.
  • Nuveen bought 3,152 Krystal Biotech shares in Q2 2026, an estimated $942K.
  • Krystal Biotech made up 0.01% of Nuveen's portfolio in Q2 2026, its #656 holding.
  • Nuveen first reported a position in Krystal Biotech in Q2 2019 and has held it in 29 quarters since.
  • Nuveen's Krystal Biotech position peaked at $61.7M in Q2 2024.
  • 424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.